Oppenheimer & Co. Inc. Sells 4,842 Shares of Allergan PLC. (AGN)

Oppenheimer & Co. Inc. reduced its stake in Allergan PLC. (NYSE:AGN) by 12.9% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 32,826 shares of the company’s stock after selling 4,842 shares during the period. Oppenheimer & Co. Inc.’s holdings in Allergan PLC. were worth $7,980,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Jacobi Capital Management LLC boosted its position in shares of Allergan PLC. by 4.9% in the 1st quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock worth $112,000 after purchasing an additional 22 shares during the last quarter. JNBA Financial Advisors lifted its holdings in Allergan PLC. by 2.5% during the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock worth $116,000 after acquiring an additional 12 shares in the last quarter. Pacific Center for Financial Services lifted its holdings in Allergan PLC. by 805.1% during the first quarter. Pacific Center for Financial Services now owns 534 shares of the company’s stock worth $128,000 after acquiring an additional 475 shares in the last quarter. Ropes Wealth Advisors LLC lifted its holdings in Allergan PLC. by 31.0% during the first quarter. Ropes Wealth Advisors LLC now owns 575 shares of the company’s stock worth $137,000 after acquiring an additional 136 shares in the last quarter. Finally, Hudock Capital Group LLC lifted its holdings in Allergan PLC. by 0.4% during the second quarter. Hudock Capital Group LLC now owns 571 shares of the company’s stock worth $138,000 after acquiring an additional 2 shares in the last quarter. Institutional investors and hedge funds own 82.02% of the company’s stock.

Several research analysts have weighed in on the company. Vetr upgraded Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 target price on the stock in a report on Monday, June 26th. Wells Fargo & Company reiterated an “outperform” rating and set a $280.00 target price (up from $270.00) on shares of Allergan PLC. in a report on Wednesday, August 9th. Citigroup Inc. reiterated a “buy” rating and set a $280.00 target price on shares of Allergan PLC. in a report on Wednesday. Morgan Stanley lowered Allergan PLC. from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $284.00 to $228.00 in a report on Wednesday. Finally, UBS AG reiterated an “outperform” rating and set a $275.00 target price on shares of Allergan PLC. in a report on Wednesday, August 9th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $273.34.

TRADEMARK VIOLATION NOTICE: This report was first reported by Transcript Daily and is owned by of Transcript Daily. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at https://transcriptdaily.com/2017/09/21/oppenheimer-co-inc-sells-4842-shares-of-allergan-plc-agn.html.

Shares of Allergan PLC. (NYSE:AGN) opened at 210.00 on Thursday. The firm has a market cap of $70.20 billion, a P/E ratio of 6.40 and a beta of 1.18. The company has a 50 day moving average price of $229.79 and a 200-day moving average price of $236.07. Allergan PLC. has a 52-week low of $184.50 and a 52-week high of $256.80.

Allergan PLC. (NYSE:AGN) last announced its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The business had revenue of $4.01 billion for the quarter, compared to analysts’ expectations of $3.95 billion. During the same quarter last year, the firm earned $3.35 EPS. The firm’s revenue for the quarter was up 8.8% compared to the same quarter last year. On average, analysts expect that Allergan PLC. will post $16.25 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Friday, September 15th. Investors of record on Friday, August 18th were given a $0.70 dividend. The ex-dividend date of this dividend was Wednesday, August 16th. This represents a $2.80 annualized dividend and a yield of 1.33%. Allergan PLC.’s payout ratio is 9.95%.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply